Skip to main content
SpringerLink
Log in

Recent Findings from Mendelian Randomization Studies of Cardiovascular Disease

  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Judgments as to causality of associations between risk factors and disease involve a weighing of the available evidence from animal and human studies. The human data include observational studies, results of which may be confounded, and randomized trials, which may be unavailable or infeasible, thus limiting the ability to make causal inference. Mendelian randomization offers an additional approach to help assess causality. The concept relies on the random assignment of alleles at meiosis as the basis for a natural randomized experiment linking genetic variants to intermediate risk factors and disease. Recent Mendelian randomization studies have provided evidence for a causal role of serum lipoprotein(a) in coronary heart disease, and against a causal role for plasma C-reactive protein. Although a valid Mendelian randomization experiment is subject to a number of assumptions and limitations, it is a useful adjunct to assess causality, especially when randomized trials are unavailable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Davey Smith G, Ebrahim S: ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003, 32:1–22.

    Article  PubMed  Google Scholar 

  2. •• Sheehan NA, Didelez V, Burton PR, Tobin MD: Mendelian randomisation and causal inference in observational epidemiology. PLoS Medicine 2008, 5:e177. This article describes the Mendelian randomization concept, summarizes key assumptions and limitations, and provides several examples to illustrate how Mendelian randomization is used in practice.

    Article  PubMed  Google Scholar 

  3. Pearson TA, Manolio TA: How to interpret a genome-wide association study. JAMA 2008, 299:1335–1344.

    Article  CAS  PubMed  Google Scholar 

  4. Greenland S: An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000, 29:722–729.

    Article  CAS  PubMed  Google Scholar 

  5. Katan MB: Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986, i:507–508.

    Article  Google Scholar 

  6. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202–1206.

    Article  PubMed  Google Scholar 

  7. Klerk M, Verhoef P, Clarke R, et al.: MTHFR 677C-->T polymorphism and risk of coronary heart disease. A meta-analysis. JAMA 2002, 288:2023–2031.

    CAS  Google Scholar 

  8. Lewis SJ, Ebrahim S, Davey Smith G: Meta-analysis of MTHFR 677C-->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005, 331:1053–1056.

    Article  CAS  PubMed  Google Scholar 

  9. Den Heijer M, Lewington S, Clarke R: Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005, 3:292–299.

    Article  Google Scholar 

  10. Cronin S, Furie KL, Kelly PJ: Dose-related association of MTHFR 677T allele with risk of ischemic stroke. Evidence from a cumulative meta-analysis. Stroke 2005, 36:1581–1587.

    Article  CAS  PubMed  Google Scholar 

  11. Casas JP, Bautista LE, Smeeth L, et al.: Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005, 365:224–232.

    CAS  PubMed  Google Scholar 

  12. Davey Smith G, Harbord R, Milton J, et al.: Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol 2005, 25:2228–2233.

    Google Scholar 

  13. Keavney B, Danesh J, Parish S, et al.: Fibrinogen and coronary heart disease: test of causality by ‘Mendelian randomization’. Int J Epidemiol 2006, 35:935–943.

    Article  PubMed  Google Scholar 

  14. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264–1272.

    Article  CAS  PubMed  Google Scholar 

  15. • Kathiresan S, Melander O, Anevski D, et al.: Polymorphisms associated with cholesterol and risk of cardiovascular events. NEJM 2008, 358:1240–1249. This article reports significant associations among SNPs at nine loci, LDL and HDL cholesterol, and incident CVD.

    Article  CAS  PubMed  Google Scholar 

  16. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al.: Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008, 299:2524–2532.

    Article  CAS  PubMed  Google Scholar 

  17. • Aulchenko YS, Ripatti S, Lindqvist I, et al.: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009, 41:47–55. In a genome-wide analysis of 16 European cohorts and up to 22,562 participants, significant associations were observed among SNPs in 16 loci, multiple serum lipid parameters, carotid IMT, and CHD incidence.

    Article  CAS  PubMed  Google Scholar 

  18. Timpson NJ, Harbord R, Davey Smith G, et al.: Does greater adiposity increase blood pressure and hypertension risk? Mendelian randomization using the FTO/MC4R genotype. Hypertension 2009, 54:84–90.

    Google Scholar 

  19. Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423–1427.

    Article  CAS  PubMed  Google Scholar 

  20. Neter JE, Stam BE, Kok FJ, et al.: Influence of weight reduction on blood pressure. A meta-analysis of randomized control trials. Hypertension 2003, 42:878–884.

    Article  CAS  PubMed  Google Scholar 

  21. • Emerging Risk Factors Collaboration: Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993–2000. This pooled analysis of more than 300,000 individuals from 68 prospective cohorts confirmed associations of serum lipids and apolipoproteins with incident CHD. The authors concluded that lipid assessment in vascular disease could be simplified to measurement of nonfasting total and HDL cholesterol levels, or apolipoproteins.

  22. Preiss D, Sattar N: Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol 2009, 70:815–828.

    Article  CAS  Google Scholar 

  23. • Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration: Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634–1639. In a pooled analysis of more than 25,000 cases and 35,000 controls, a SNP in the APOA5 gene was associated with serum triglyceride levels and CHD risk, but interpretation is complicated by the association of the SNP with HDL levels (pleiotropy).

  24. Kamstrup PR: Lipoprotein(a) and ischemic heart disease—a causal association? A review. Atherosclerosis 2010, 211:15–23.

    Article  CAS  PubMed  Google Scholar 

  25. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 102:1082–1085.

    CAS  PubMed  Google Scholar 

  26. • Emerging Risk Factors Collaboration: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412–423. In a pooled analysis of more than 125,000 individuals from 36 studies, elevated lipoprotein(a) levels were associated with increased risk of CHD and stroke.

  27. •• Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331–2339. Genetic variants were associated with lipoprotein(a) levels and myocardial infarction risk in case-control and prospective Copenhagen cohorts. The magnitude of the genetic variant-CHD effect was consistent with observational findings for lipoprotein(a) levels.

    Article  CAS  PubMed  Google Scholar 

  28. •• Clarke R, Peden JF, Hopewell JC, et al.: Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518–2528. Genetic variants were associated with lipoprotein(a) levels and CHD risk in a pooled analysis of 4 case-control studies.

    Article  CAS  PubMed  Google Scholar 

  29. Rifai N, Ma J, Sacks FM, et al.: Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians’ Health Study. Clin Chem 2004, 50:1364–1371.

    Article  CAS  PubMed  Google Scholar 

  30. Paultre F, Pearson TA, Weil HF, et al.: High levels of Lp(a) with a small Apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000, 20:2619–2624.

    CAS  PubMed  Google Scholar 

  31. Verma S, Szmitko PE, Ridker PM: C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005, 2:29–36.

    Article  CAS  PubMed  Google Scholar 

  32. Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387–1397.

    Article  CAS  PubMed  Google Scholar 

  33. Shah T, Casas JP, Cooper JA, et al.: Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009, 38:217–231.

    Article  PubMed  Google Scholar 

  34. Casas JP, Shah T, Cooper J, et al.: Insight into the nature of the CRP-coronary even association using Mendelian randomization. Int J Epidemiol 2006, 35:922–931.

    Article  PubMed  Google Scholar 

  35. Kardys I, de Maat MP, Uitterlinden AG, et al.: C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. Eur Heart J 2006, 27:1331–1337.

    Article  CAS  PubMed  Google Scholar 

  36. Lawlor DA, Harbord RM, Timpson NJ, et al.: The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants. PLoS One 2008, 3:e3011.

    Article  PubMed  Google Scholar 

  37. • Zacho J, Tybjærg-Hansen A, Skov Jensen J, et al.: Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008, 359:1897–1908. Genetic variants were associated with CRP levels, but not CHD or stroke, in a pooled analysis of cross-sectional, case-control and prospective Copenhagen cohorts.

    Article  CAS  PubMed  Google Scholar 

  38. •• Elliott P, Chambers JC, Zhang W, et al.: Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009, 302:37–48. Genetic variants were associated with CRP levels, but not CHD risk, in pooled analysis of 25 case-control and prospective studies involving more than 28,000 cases and 100,000 controls. This article provides the most compelling evidence to date that raised CRP levels are a consequence, rather than a cause, of CHD.

    Article  CAS  PubMed  Google Scholar 

  39. Kivimäki M, Lawlor DA, Eklund C, et al.: Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the Young Finns Study. Arterioscler Thromb Vasc Biol 2007, 27:978–979.

    Article  PubMed  Google Scholar 

  40. Kivimäki M, Lawlor DA, Davey Smith G, et al.: Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS One 2008, 3:e3013.

    Article  PubMed  Google Scholar 

  41. • Casas JP, Ninio E, Panayiotou A, et al.: PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10494 cases and 15624 controls of European Ancestry. Circulation 2010, 121:2284–2293. Genetic variants were associated with small but significant differences in Lp-PLA 2 activity levels, but not CHD risk, in pooled analysis of 12 studies.

    Article  CAS  PubMed  Google Scholar 

  42. • Lp-PLA2 Studies Collaboration: Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536–1544. In a pooled analysis of more than 79,000 individuals from 32 prospective studies, elevated Lp-PLA 2 activity and mass were associated with increased risk of CHD, stroke, total vascular disease, and nonvascular disease.

  43. Hou L, Chen S, Yu H, et al.: Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009, 125:11–20.

    Article  CAS  PubMed  Google Scholar 

  44. Enomoto N, Takase S, Yasuhara M, Takada A: Acetaldehyde metabolism in different aldehyde dehydrogenase-2 genotypes. Alcohol Clin Exp Res 1991, 15:141–144.

    Article  CAS  PubMed  Google Scholar 

  45. • Chen L, Davey Smith G, Harbord RM, Lewis SJ: Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Medicine 2008, 5:e52. A genetic variant in the ALDH2 gene was associated with reduced alcohol consumption, reduced blood pressure, and reduced risk of prevalent hypertension in a pooled analysis of eight studies of Japanese men. This article demonstrates how the Mendelian randomization concept can be used to assess the causality of behavioral exposures, rather than intermediate phenotypes.

    Article  PubMed  Google Scholar 

  46. Marmot MG, Elliott P, Shipley MJ, et al.: Alcohol and blood pressure: the INTERSALT Study. BMJ 1994, 308:1263–1267.

    CAS  PubMed  Google Scholar 

  47. Fuchs FD, Chambless LE, Whelton PK, et al.: Alcohol consumption and the risk of incidence of hypertension: the Athersclerosis Risk in Communities Study. Hypertension 2001, 37:1242–1250.

    CAS  PubMed  Google Scholar 

  48. Thanassoulis G, O’Donnell CJ: Mendelian randomization: nature’s randomized trial in the post-genome era. JAMA 2009, 301:2386–2388.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

PE has received grants from the UK Medical Research Council and the UK British Heart Foundation. No other potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, St. Mary’s Campus, Norfolk Place, London, W2 1PG, UK

    Ian J. Brown & Paul Elliott

  2. MRC-HPA Centre for Environment and Health, Imperial College London, London, UK

    Paul Elliott

Authors
  1. Ian J. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Elliott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Elliott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, I.J., Elliott, P. Recent Findings from Mendelian Randomization Studies of Cardiovascular Disease. Curr Cardio Risk Rep 4, 429–436 (2010). https://doi.org/10.1007/s12170-010-0127-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-010-0127-3

Keywords

Search

Navigation